ReviewCancer pathogenesis and therapy2024

Dostarlimab in the treatment of mismatch repair deficient recurrent or advanced endometrial cancer.

Siddhant Shukla et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.